medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2020, Number 4

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2020; 36 (4)

Characterization of adult patients with diffuse large B-cell non-Hodgkin lymphoma

Quintero SY, Concepción FY, Hernández PC, Romero GA, Pérez IM, Lam RM

Language: Spanish
References: 24
Page: 1-17
PDF size: 369.04 Kb.


ABSTRACT

Introduction: Diffuse large B-cell lymphoma is the most common subtype of aggressive non-Hodgkin lymphoma.
Objective: Characterize the behavior of adult patients with diffuse large B-cell lymphoma.
Methods: An observational retrospective longitudinal descriptive study was conducted of 56 adult patients with diffuse large B-cell lymphoma attending the Institute of Hematology and Immunology from January 1998 to December 2018.
Results: Of the patients studied, 55.4% were male, and a predominance was found of white skin color (76.8%) and the 59-78 years age group (44.6%). Patients with comorbidities prevailed, mainly hypertension (35.7%) with an ability to perform activities of daily living (55.4%). 53.6% of the patients were in stage IV at diagnosis. Patients with type B symptoms prevailed with 85.7%, and the low to intermediate risk group was the most common with 35.7%. The regimen most frequently used was R-CHOP, obtaining 85.7% complete remission. 17.9% of the patients died and 41.1% relapsed. Overall survival at 3, 5 and 10 years was 87.0%, 83.0% and 80.0%, respectively. Disease-free survival at 3, 5 and 10 years was 74.0%, 67% and 56%, respectively.
Conclusions: Overall and disease-free survival were high.


REFERENCES

  1. Martelli M, Ferreri AJM, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013 Aug;87(2):146-71.

  2. Guevara NM, Jaramillo PE, Rendón J, Gaviria LM. Caracterización de factores pronósticos al diagnóstico de pacientes con Linfoma B difuso de células grandes en un Hospital Universitario, 2009-2012. Acta Med Colomb [Internet]. 2014[acceso 15/01/2013];39: 137-147. Disponible en: http://www.scielo.org.co/pdf/amc/v39n2/v39n2a09.pdf

  3. Dunleavy K, Wilson WH. Diagnosis and Treatment of Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma. In: Hoffman R, Benz EJ, Silberstein LE, Heslop HE, Weitz JI, Anastasi J, et al. Hematology: Basic Principles and Practice.7th Ed. Elsevier; 2017. p.1309-17.

  4. Nicolae A, Pittaluga S, Abdullah S, Steinberg SM, Pham TA, Davies-Hill T, et al. EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood. 2015 Aug 13;126(7):863-72.

  5. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May;127(20):2375-90. DOI: https://10.1182/blood-2016-01-643569

  6. Shipp MA, Harrington DP, Anderson JR, Armitage JO, Bonadonna G, Brittingeret G, et al. A predictive model for agressive non-Hodgkin´s lymphoma: The international non-Hodgkin´s lymphoma prognostic factors project. N Engl J Med 1993; 329 (14):987-94.

  7. Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, et al. Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies. J Clin Oncol. 2015 Sep;33(26):2848-56.

  8. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007 Mar;109(5):1857-61. DOI: https://10.1182/blood-2006-08-038257

  9. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol. 2014; 32:3059-67.

  10. Vitolo U, Seymour JF, Martelli M, Illerhaus G, Illidge T, Zucca E, et al. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v91-102.

  11. Cruz D, Reyes EN, Limón A, Mendoza A, Gutiérrez C, Pérez M, et al. Frecuencia y variedades de linfomas en un hospital de concentración público mexicano de tercer nivel. Rev Hematol Mex [Internet]. 2015 Ene-Mar [acceso 11/09/2017];16:9-16. Disponible en: http://www.medigraphic.com/pdfs/hematologia/re-2015/re151c.pdf

  12. Gómez Y, García D, Trujillo L. Supervivencia de los pacientes con linfoma no Hodgkin difuso B de células grandes. Acta Medic. Centro. 2017;11(3):2-12

  13. Quintero ODI. Linfoma Non Hodgkin Difuso de Células Grandes B. Rev Med Cos Cen.2014;71(610):333-38.

  14. Freedman AS, Jacobson CA, Mauch P, Aster JC. Non-Hodgkin lymphoma. In: De Vita VT. Cancer Principles & Practice of Oncology.10ma ed. Philadelphia: Wolters Kluwer; 2015. p. 1552-83.

  15. Mejía Freire SA, Molina Calderón AA. Características, clínicas, demográficas e histopatológicas de pacientes con linfomas no Hodgkin [tesis]. Ecuador: Universidad del Azuay; 2015. [acceso 15/01/2017]. Disponible en: Disponible en: http://dspace.uazuay.edu.ec/bitstream/datos/5006/1/11444.pdf

  16. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: B-cell lymphomas. V.1.2017. Washington, PA: NCCN; 2016. acceso 07/12/2016. Disponible en: Disponible en: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf

  17. Sehn LH, Gascoyne RD: Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood.2015 Jan;125(1):22-32. DOI: https://10.1182/blood-2014-05-577189

  18. Zhou Z, Sehn LH, Rademaker AW, Gordon LI, LaCasce AS, Crosby-Tompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014 Feb 6;123(6):837-42. DOI: https://10.1182/blood-2013-09-524108

  19. Montalban C, Diaz-Lopez A, Dlouhy I, Rovira J, Lopez-Guillermo A, Alonso S, et al. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of beta2 -microglobulin yields a more accurate GELTAMO-IPI. Br J Haematol. 2017;176:918-28.

  20. Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2010;29(2):200-7.

  21. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium. Leukemia. 2012 Sep;26(9):2103-13.

  22. Coutinho R, Clear AJ, Owen A, Wilson A, Matthews J, Lee A. Poor concordance among in e immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: Implications for therapeutic strategies. Clin Cancer Res. 2013 Dec 15;19(24):6686-95.

  23. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9 (2):105-16.

  24. Cuba. Ministerio de Salud Pública. Anuario estadístico de Salud 2015. [Internet]. La Habana: Dirección de Registros Médicos y Estadísticas de Salud; 2016 [acceso 11/09/2017]. Disponible en: Disponible en: http://files.sld.cu/dne/files/2016/04/Anuario_2015_electronico-1.pdf




2020     |     www.medigraphic.com